ADVFN Logo
Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

ACRS Aclaris Therapeutics Inc

1.18
0.01 (0.85%)
Mar 18 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 865,679
Bid Price 1.09
Ask Price 1.22
News -
Day High 1.20

Low
0.5902

52 Week Range

High
11.12

Day Low 1.135
Company Name Stock Ticker Symbol Market Type
Aclaris Therapeutics Inc ACRS NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.01 0.85% 1.18 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.16 1.135 1.20 1.15 1.17
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
4,112 865,679 $ 1.17 $ 1,009,119 - 0.5902 - 11.12
Last Trade Time Type Quantity Stock Price Currency
19:36:47 formt 100 $ 1.18 USD

Aclaris Therapeutics Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
81.56M 70.93M - 29.75M -86.91M -1.23 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Aclaris Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No ACRS Message Board. Create One! See More Posts on ACRS Message Board See More Message Board Posts

Historical ACRS Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week1.331.451.111.211,282,339-0.15-11.28%
1 Month1.181.511.111.241,454,3320.000.00%
3 Months1.071.510.85551.151,903,4370.1110.28%
6 Months7.547.540.59021.433,155,196-6.36-84.35%
1 Year8.0311.120.59022.731,939,881-6.85-85.31%
3 Years24.0030.3750.59027.45999,143-22.82-95.08%
5 Years5.6130.3750.59027.561,021,681-4.43-78.97%

Aclaris Therapeutics Description

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Your Recent History

Delayed Upgrade Clock